Core Data & Financials:
- The Deal: CVC Capital Partners ($CVC.AS) and Belgian holding group GBL ($GBLB.BR) co-launched a formal €10.7 billion ($12.4 billion) voluntary cash tender offer to buy out and delist Italian drugmaker Recordati ($RECI.MI).
- The Offer Price: €51.29 per share in cash (ex-dividend). This represents a 12.89% premium over Recordati’s share price on March 25, 2026, right before CVC’s initial interest was made public.
- Consortium Backing: A heavyweight investor lineup is backing the bid, including the Abu Dhabi Investment Authority (ADIA), Canada Pension Plan Investment Board (CPPIB), PSP Europe, and a vehicle controlled by company chairman Andrea Recordati.
- Target Thresholds: The consortium aims for a 90% acceptance rate to trigger an automatic squeeze-out and delisting. However, they structurally secured a 66.67% voting minimum allowing them to force a merger by incorporation if needed.
Why It Matters:
- Scale & Consolidation: This transaction marks the largest European pharmaceuticals deal and the biggest leveraged buyout announced globally so far in 2026. It underscores a massive wave of consolidation sweeping across Italy’s fragmented drug sector (e.g., Angelini’s recent $4.1B buy of Catalyst and Chiesi’s $2B purchase of KalVista).
- The Rare Disease Pivot: Recordati, which achieved €2.62 billion in 2025 revenue, has evolved from a century-old family pharmacy into a specialty powerhouse. Private ownership is designed to aggressively accelerate R&D and pipeline acquisitions within its highly lucrative, high-margin rare diseases platform.